CAMBRIDGE, Mass., Nov. 11 /PRNewswire/ -- Quanterix Corporation, the
leader in single molecule detection, announced today that Robert Corn, Ph.D.
has joined its Scientific Advisory Board (SAB). Dr. Corn is a Professor in
the Departments of Chemistry and Biomedical Engineering at the University of
California, Irvine. Dr. Corn's primary research areas include the development
of new methods for detecting binding of biomolecules to surfaces and chemical
modification strategies to control specific and non-specific adsorption of
biopolymers to a variety of surfaces.
Dr. David Walt, Scientific Founder of Quanterix and Chair of the SAB,
stated, "Dr. Corn is a leader in the field of surface chemistry; his research
interests and experience are directly applicable to our Single Molecule Array
(SiMoA(TM)) technology. We are eager to draw upon his extensive knowledge and
insight as we develop assays and instrumentation that enable unparalleled
increases in analytical sensitivity for the detection of proteins implicated
in a variety of diseases."
Dr. Corn added, "The novel technology platform being developed by
Quanterix will provide medical researchers with a unique tool that allows low
abundance biomarkers to be detected in complex biological samples. I am
excited to join such a world class Advisory Board and look forward to working
with the other members to further advance this promising technology."
Dr. Corn joins SAB members David Walt, Ph.D., Robinson Professor of
Chemistry and Howard Hughes Medical Institute Professor, Tufts University
(Chairman of the SAB), Larry J. Kricka, D. Phil., Professor of Pathology and
Laboratory Medicine at the University of Pennsylvania and Director of the
General Chemistry Laboratory at the Hospital of the University of
Pennsylvania, J. Michael Ramsey, Ph.D., Minnie N. Goldby Distinguished
Professor of Chemistry and Chair at the University of North Carolina at Chapel
Hill, and Sunney Xie, Ph.D., Professor of Chemistry at Harvard University.
Quanterix is developing a revolutionary Single Molecule Array (SiMoA(TM))
technology that allows the behavior of thousands of individual molecules to be
observed simultaneously, rather than an ensemble average of many molecules as
with existing technologies. Quanterix's platform will bring an unprecedented
level of sensitivity, precision, and assay robustness to clinical diagnostics,
drug development, and life science research. The first application that
Quanterix is pursuing with the SiMoA(TM) technology is the detection and
quantification of proteins present in blood and other body fluids at very low,
previously undetectable, concentrations. Diagnostic assays targeting proteins
that have been implicated in a variety of human diseases, including cancer,
chronic inflammatory disease and cardiovascular disease are under development.
Quanterix is a privately held company located in Cambridge, Massachusetts and
is backed by leading life science investors including ARCH Venture Partners,
Bain Capital Ventures, and Flagship Ventures. For additional information,
please visit http://www.quanterix.com.
SOURCE Quanterix Corporation